A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride)

A Case Report

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hidradenitis suppurativa (HS) is a challenging skin disease with limited therapeutic options. Obesity and metabolic syndrome are being increasingly implicated and associated with younger ages and greater metabolic severity. A 19-year-old female with an 8-year history of progressively debilitating cicatricial HS disease presented with obesity, profound anemia, leukocytosis, increased platelet count, hypoalbuminemia, and elevated liver enzymes. A combination of metformin, liraglutide, levonorgestrel-ethinyl estradiol, dapsone, and finasteride was initiated. Acute antibiotic use for recurrences and flares could be slowly discontinued. Over the course of 3 years on this regimen, the liver enzymes normalized in 1 year, followed in2 years by complete resolution of the majority of the hematological and metabolic abnormalities. The sedimentation rate reduced from over 120 to 34 mm/h. She required 1 surgical intervention for perianal disease after 9 months on the regimen. Flares greatly diminished in intensity and duration, with none in the past 6 months. Right axillary lesions have completely healed with residual disease greatly reduced. Chiefly abdominal lesions are persistent. She was able to complete high school from home, start a job, and resume a normal life. Initial weight loss of 40 pounds was not maintained. The current regimen is being well tolerated and continued.

Original languageEnglish (US)
Pages (from-to)70-78
Number of pages9
JournalCase Reports in Dermatology
DOIs
StateAccepted/In press - Jul 13 2017

Fingerprint

Hidradenitis Suppurativa
Finasteride
Dapsone
Metformin
Job Application
Obesity
Hypoalbuminemia
Liver
Leukocytosis
Enzymes
Platelet Count
Skin Diseases
Anemia
Weight Loss
Anti-Bacterial Agents
Recurrence
Liraglutide
Therapeutics

Keywords

  • Acne inversa
  • Anemia
  • Dapsone
  • Elevated liver enzymes
  • Elevated platelet count
  • Elevated sedimentation rate
  • Finasteride
  • Hidradenitis suppurativa
  • Leukocytosis
  • Liraglutide
  • Metabolic syndrome
  • Metformin
  • Obesity
  • Thrombocytosis
  • Weight loss

ASJC Scopus subject areas

  • Dermatology

Cite this

@article{d3f11b3072154908a22618fcb6a2481e,
title = "A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride): A Case Report",
abstract = "Hidradenitis suppurativa (HS) is a challenging skin disease with limited therapeutic options. Obesity and metabolic syndrome are being increasingly implicated and associated with younger ages and greater metabolic severity. A 19-year-old female with an 8-year history of progressively debilitating cicatricial HS disease presented with obesity, profound anemia, leukocytosis, increased platelet count, hypoalbuminemia, and elevated liver enzymes. A combination of metformin, liraglutide, levonorgestrel-ethinyl estradiol, dapsone, and finasteride was initiated. Acute antibiotic use for recurrences and flares could be slowly discontinued. Over the course of 3 years on this regimen, the liver enzymes normalized in 1 year, followed in2 years by complete resolution of the majority of the hematological and metabolic abnormalities. The sedimentation rate reduced from over 120 to 34 mm/h. She required 1 surgical intervention for perianal disease after 9 months on the regimen. Flares greatly diminished in intensity and duration, with none in the past 6 months. Right axillary lesions have completely healed with residual disease greatly reduced. Chiefly abdominal lesions are persistent. She was able to complete high school from home, start a job, and resume a normal life. Initial weight loss of 40 pounds was not maintained. The current regimen is being well tolerated and continued.",
keywords = "Acne inversa, Anemia, Dapsone, Elevated liver enzymes, Elevated platelet count, Elevated sedimentation rate, Finasteride, Hidradenitis suppurativa, Leukocytosis, Liraglutide, Metabolic syndrome, Metformin, Obesity, Thrombocytosis, Weight loss",
author = "Khandalavala, {Birgit N}",
year = "2017",
month = "7",
day = "13",
doi = "10.1159/000473873",
language = "English (US)",
pages = "70--78",
journal = "Case Reports in Dermatology",
issn = "1662-6567",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - A Disease-Modifying Approach for Advanced Hidradenitis Suppurativa (Regimen with Metformin, Liraglutide, Dapsone, and Finasteride)

T2 - A Case Report

AU - Khandalavala, Birgit N

PY - 2017/7/13

Y1 - 2017/7/13

N2 - Hidradenitis suppurativa (HS) is a challenging skin disease with limited therapeutic options. Obesity and metabolic syndrome are being increasingly implicated and associated with younger ages and greater metabolic severity. A 19-year-old female with an 8-year history of progressively debilitating cicatricial HS disease presented with obesity, profound anemia, leukocytosis, increased platelet count, hypoalbuminemia, and elevated liver enzymes. A combination of metformin, liraglutide, levonorgestrel-ethinyl estradiol, dapsone, and finasteride was initiated. Acute antibiotic use for recurrences and flares could be slowly discontinued. Over the course of 3 years on this regimen, the liver enzymes normalized in 1 year, followed in2 years by complete resolution of the majority of the hematological and metabolic abnormalities. The sedimentation rate reduced from over 120 to 34 mm/h. She required 1 surgical intervention for perianal disease after 9 months on the regimen. Flares greatly diminished in intensity and duration, with none in the past 6 months. Right axillary lesions have completely healed with residual disease greatly reduced. Chiefly abdominal lesions are persistent. She was able to complete high school from home, start a job, and resume a normal life. Initial weight loss of 40 pounds was not maintained. The current regimen is being well tolerated and continued.

AB - Hidradenitis suppurativa (HS) is a challenging skin disease with limited therapeutic options. Obesity and metabolic syndrome are being increasingly implicated and associated with younger ages and greater metabolic severity. A 19-year-old female with an 8-year history of progressively debilitating cicatricial HS disease presented with obesity, profound anemia, leukocytosis, increased platelet count, hypoalbuminemia, and elevated liver enzymes. A combination of metformin, liraglutide, levonorgestrel-ethinyl estradiol, dapsone, and finasteride was initiated. Acute antibiotic use for recurrences and flares could be slowly discontinued. Over the course of 3 years on this regimen, the liver enzymes normalized in 1 year, followed in2 years by complete resolution of the majority of the hematological and metabolic abnormalities. The sedimentation rate reduced from over 120 to 34 mm/h. She required 1 surgical intervention for perianal disease after 9 months on the regimen. Flares greatly diminished in intensity and duration, with none in the past 6 months. Right axillary lesions have completely healed with residual disease greatly reduced. Chiefly abdominal lesions are persistent. She was able to complete high school from home, start a job, and resume a normal life. Initial weight loss of 40 pounds was not maintained. The current regimen is being well tolerated and continued.

KW - Acne inversa

KW - Anemia

KW - Dapsone

KW - Elevated liver enzymes

KW - Elevated platelet count

KW - Elevated sedimentation rate

KW - Finasteride

KW - Hidradenitis suppurativa

KW - Leukocytosis

KW - Liraglutide

KW - Metabolic syndrome

KW - Metformin

KW - Obesity

KW - Thrombocytosis

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=85023749325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023749325&partnerID=8YFLogxK

U2 - 10.1159/000473873

DO - 10.1159/000473873

M3 - Article

SP - 70

EP - 78

JO - Case Reports in Dermatology

JF - Case Reports in Dermatology

SN - 1662-6567

ER -